hero img

Yescarta® offers hope for complete remission

YESCARTA is the first CAR T therapy for adults living with certain types of non-Hodgkin lymphoma. YESCARTA is different from other cancer treatments because it is made from your own white blood cells, which have been modified to recognize and destroy cancer cells.

How to get started when
you're considering Yescarta

First, download the CAR T Discussion Tool

This discussion guide provides questions you can ask your oncologist to better understand all of your treatment options.

Review these questions with your oncologist, or an oncologist at an Authorized Treatment Center, to learn about YESCARTA therapy.

Next, find an oncologist with YESCARTA experience

YESCARTA is available at Authorized Treatment Centers with medical staff thoroughly trained and equipped to provide this treatment. These centers are leaders in innovative cancer care.

Oncologists at Authorized Treatment Centers have the most experience with CAR T therapy and will be your most informed option for discussing YESCARTA.

YESCARTA makes complete remission possible

In a clinical study of 101 patients with non-Hodgkin lymphoma who had failed other treatments, YESCARTA was shown to help 51% (52 out of 101) of patients achieve complete remission with ~9-month minimum follow-up.

Rapid and ongoing results

  • People generally responded to treatment within 1 month (range: 0.8–6.2 months)
  • For those who achieved complete remission, the response was generally ongoing
remission chart

Complete Remission: The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.

Partial Remission: A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.

quote iconNearly 8 weeks from my infusion date, I had my first PET scan, which revealed no signs of cancer.quote icon

—Gary, a real YESCARTA patient

Not all patients will experience the same results and side effects may vary.

Ongoing clinical study results
At a 2-year follow-up, over half of patients treated with YESCARTA were still living

  • YESCARTA was studied in a clinical trial of 101 patients with non-Hodgkin lymphoma who had failed other treatments. The FDA approved this therapy based on how many patients could achieve complete remission and how long that response would last
  • A secondary goal in the study was how long they lived overall. At the 2-year follow-up, more than half of patients treated with YESCARTA were still alive. Not all of these patients stayed in remission